Ingredient sheet 18-025
Syn®-Ake
Syn®-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate)
Classification
- Platform category
- Regional Signature Component (Level 5)
- Functional layer
- Regional Signature Components
- Ingredient classification
- Synthetic Bioactive Peptide · Cutaneous topical Active Ingredient · Regional Signature Component · Neuromodulatory Peptide
SIRIAM Platform role
Within the SIRIAM Platform, Syn®-Ake is classified as a Regional Signature Component.
Unlike the Structural & Dermal Support Core, Release Core and Integration Core ingredients, Syn®-Ake is incorporated selectively into regional formulations according to their intended neurodermal objectives.
Within the architectural philosophy of the SIRIAM Platform, Syn®-Ake represents one of the few synthetic biomimetic molecules, complementing the predominantly botanical and naturally derived ingredients. Its inclusion broadens the platform by integrating modern peptide technology into anatomically targeted formulations.
Its incorporation reflects the SIRIAM principle of combining evidence-based cutaneous topical biotechnology with region-specific neurodermal formulation design.
Scientific rationale
Syn®-Ake is the commercial name for Dipeptide Diaminobutyroyl Benzylamide Diacetate, a synthetic biomimetic peptide developed to mimic selected structural characteristics of Waglerin-1, a peptide originally isolated from the venom of the Temple Viper (Tropidolaemus wagleri).
Importantly, Syn®-Ake is not venom, nor does it contain venom-derived proteins. It is a chemically synthesised peptide designed for cutaneous topical application.
Experimental investigations indicate that Syn®-Ake interacts with nicotinic acetylcholine receptors (nAChRs) located at the neuromuscular junction. In vitro studies suggest that the peptide may partially and reversibly reduce receptor activation, thereby decreasing muscle contraction under laboratory conditions.
Unlike botulinum neurotoxin, Syn®-Ake:
does not inhibit acetylcholine release;
does not produce neuromuscular paralysis;
acts through reversible receptor interaction rather than presynaptic neurotransmitter blockade.
Commercial development has therefore focused primarily on cutaneous topical reduction of dynamic facial wrinkles, particularly those associated with repetitive superficial muscle activity.
Human clinical evidence consists mainly of manufacturer-sponsored cutaneous topical studies evaluating:
wrinkle appearance;
skin smoothness;
facial relaxation;
cutaneous topical perception.
Published independent clinical research remains relatively limited, although available data suggest good dermal tolerability.
Experimental studies investigating anti-inflammatory, regenerative or peripheral neurophysiological effects remain sparse.
No published studies currently investigate Syn®-Ake within a region-specific neurodermal formulation architecture comparable to the SIRIAM Platform.
Consequently, its inclusion reflects pharmaceutical plausibility together with the architectural philosophy of the platform rather than established evidence for this specific neurodermal application.
Pharmaceutical considerations
Physicochemical Characteristics
- Synthetic peptide
- Water-soluble
- Low molecular weight cutaneous topical active
- Stable under mildly acidic to neutral pH
- Sensitive to prolonged high temperatures
Formulation Considerations
Within the SIRIAM Platform, Syn®-Ake is incorporated into the aqueous phase during the final stages of manufacture.
Important pharmaceutical considerations include:
pharmaceutical-grade peptide quality;
preservation from excessive heat during production;
compatibility with peptide-stabilising formulation conditions;
avoidance of strong oxidising environments;
maintenance of appropriate formulation pH.
Peptide integrity should be preserved throughout manufacture to optimise long-term stability.
Safety Considerations
Current cutaneous topical safety data demonstrate excellent dermal tolerability.
Available evidence indicates:
very low irritation potential;
very low sensitisation risk;
absence of systemic neuromuscular toxicity when used at cutaneous topical concentrations;
favourable long-term cutaneous topical safety profile.
Because Syn®-Ake acts through reversible receptor interaction, systemic pharmacological effects are not expected following topical cutaneous topical application.
Packaging
Opaque airless dispensers are recommended to minimise peptide degradation and preserve long-term formulation stability.
Current role within the platform
Within the SIRIAM Platform, Syn®-Ake functions as a Regional Signature Component.
Unlike most Regional Signature botanicals, Syn®-Ake represents a modern synthetic peptide selected for its potential interaction with superficial neuromuscular physiology.
Its architectural role is to complement selected regional formulations requiring a biomimetic peptide component while remaining distinct from the universal platform architecture.
Future optimisation may refine peptide concentration and incorporation methodology according to pharmaceutical development.
Development notes
Development Notes
Current pharmaceutical development supports continued evaluation of Syn®-Ake as a Regional Signature Component.
Future optimisation may include:
optimisation of peptide concentration;
compatibility studies with neighbouring botanical ingredients;
evaluation of long-term peptide stability;
optimisation of aqueous phase incorporation;
assessment of formulation performance within complete regional systems.
Future pharmaceutical validation should evaluate the complete SIRIAM formulation rather than the isolated peptide.
Evidence classification
- Level
- B (cutaneous topical evidence); C (experimental neurophysiology); C (regional neurodermal application)
- Assessment
- Moderate cutaneous topical evidence supports wrinkle reduction through reversible modulation of nicotinic acetylcholine receptor activity. Experimental evidence supports its proposed mechanism of action. Independent clinical evidence remains limited, and no published studies currently evaluate Syn®-Ake within region-specific neurodermal formulation systems such as the SIRIAM Platform.
Relationships
Regional Signature association
Platform association
Neuromodulatory association
Cross references
- Chapter 12 — Structural Matrix
- Chapter 13 — Functional Matrix
- Chapter 15 — Ingredient Design Strategy
- Chapter 17 — Regional Signature Design
- Relevant Regional Master Formulae